Addyi and Testosterone: Is It Safe to Take Both for Low Sex Drive?

What Is the Interaction Between Flibanserin and Testosterone?

The combination does not produce a single dramatic drug-drug interaction the way a CYP3A4 inhibitor does with flibanserin. Instead, you are dealing with a cluster of pharmacodynamic overlaps and shared monitoring needs that clinicians must manage actively. Flibanserin is a serotonin 1A receptor agonist and serotonin 2A receptor antagonist that also has dopamine D4 partial agonist activity, and its metabolism runs almost entirely through CYP3A4 and, to a lesser degree, CYP2C19. Testosterone is not a meaningful CYP3A4 inhibitor or inducer at physiologic female doses, so the pharmacokinetic clash that you would worry about with, say, a fluconazole co-prescription is not the primary concern here.

The real concerns are:

• Androgenic effects on the same CNS pathways that flibanserin modulates
• Shared cardiovascular risk signals (polycythemia, lipid changes) that require coordinated tracking
• Off-label status of testosterone in women creating regulatory and monitoring blind spots
• Hormone-level variability across the menstrual cycle altering both drugs' apparent effects

How Flibanserin Works in the Female Brain

Flibanserin was designed to shift the balance of excitatory and inhibitory neurotransmitters involved in sexual desire. In the prefrontal cortex, it reduces serotonin and increases dopamine and norepinephrine. This is a fundamentally different mechanism from PDE5 inhibitors, which act on genital blood flow. The key BEGONIA trial showed that premenopausal women on flibanserin 100 mg nightly reported approximately 0.5 more satisfying sexual events per month compared with placebo, a statistically significant but modest effect. Understanding this CNS-centric mechanism matters because androgens also modulate dopaminergic tone, which is where the pharmacodynamic story gets complicated.

How Testosterone Affects Female Sexual Desire

Testosterone in women is produced by the ovaries and adrenal glands and peaks in the mid-follicular phase. Total testosterone in reproductive-age women typically runs 15-70 ng/dL, compared with 300-1000 ng/dL in men. Even at these lower concentrations, androgens bind to receptors in limbic structures involved in desire, motivation, and reward. When you add exogenous testosterone, you are reinforcing the same dopaminergic reward pathways that flibanserin is trying to upregulate via serotonin suppression. The theoretical result is additive benefit, but the empirical data from co-administration studies in women are essentially absent.

Pharmacokinetic Details: Does Testosterone Change How Addyi Is Metabolized?

Short answer: probably not in a clinically significant way. Here is why.

Flibanserin is metabolized primarily by CYP3A4 with minor contributions from CYP2C19. Testosterone at the doses used in female therapy (transdermal 0.5-2 mg/day or intramuscular at very low doses) does not induce or inhibit CYP3A4 at levels that would change flibanserin plasma exposure meaningfully. The FDA label for flibanserin identifies strong CYP3A4 inhibitors (azole antifungals, certain HIV antiretrovirals, some SSRIs) and strong inducers (rifampin, carbamazepine, St. John's wort) as contraindicated or requiring dose adjustment. Testosterone is in neither category.

P-glycoprotein (P-gp) transport is less relevant here because flibanserin is not a major P-gp substrate, and testosterone does not substantially inhibit P-gp at female physiologic doses.

CYP2C19 Consideration

Women who are CYP2C19 poor metabolizers may accumulate higher flibanserin plasma levels. This is a sex-relevant pharmacokinetic point because women are overrepresented in the poor-metabolizer phenotype for CYP2C19 compared with men, meaning flibanserin sedation risk may be higher in women even at standard dosing. Testosterone does not change CYP2C19 activity, but knowing your patient's metabolizer status matters when you are stacking a CNS-active agent.

The Alcohol Black-Box Warning Still Applies

No matter what else you are taking, the FDA's black-box warning on flibanserin prohibits alcohol use within the same day. The SUNFISH study, which was the dedicated alcohol interaction study, showed that co-ingestion produced severe hypotension and syncope in a majority of participants. Testosterone does not amplify this risk directly, but the warning does not disappear because you are also on testosterone.

Pharmacodynamic Interactions: Where the Real Clinical Overlap Lives

This is the section that matters most clinically.

CNS and Hormonal Crosstalk

Estrogen and testosterone modulate serotonin receptor density and sensitivity. The estrogen-testosterone ratio shifts significantly across the menstrual cycle, across perimenopause, and after surgical menopause. Because flibanserin's mechanism depends on serotonin 1A and 2A receptor activity, changes in sex hormone concentrations may alter the drug's apparent effect. A 2014 analysis in Menopause noted that the neuroendocrine milieu of estrogen and androgen levels shapes serotonin receptor expression in limbic regions relevant to sexual desire. This means that when you are simultaneously giving exogenous testosterone, you may be changing the very receptor environment that flibanserin is targeting, with unpredictable directional effects.

Cardiovascular Signal: Polycythemia and Lipids

Testosterone therapy in women, even at low doses, carries a risk of erythrocytosis (elevated hematocrit) and adverse lipid shifts, particularly suppression of HDL. The Global Consensus Position Statement on testosterone use in women, published in 2019 and co-signed by The Menopause Society, states that hematocrit and lipids should be checked at baseline and at 3-6 months after initiation. Flibanserin does not independently raise hematocrit, but it can produce dizziness and hypotension, especially in the first few weeks of use. If hematocrit is climbing from testosterone and blood pressure is already fluctuating from flibanserin, the combination creates a more complex hemodynamic picture than either drug alone.

Hepatic Considerations

Flibanserin carries a warning for hepatic impairment: the drug is contraindicated in women with any degree of hepatic impairment because CYP3A4 processing is liver-dependent and plasma levels rise sharply when liver function is compromised. Oral testosterone (not the typical female route, but used in some compounded preparations) is hepatotoxic. Transdermal testosterone avoids the hepatic first pass and is the preferred female route precisely for this reason. If your prescriber is using an oral testosterone compound, liver enzyme monitoring becomes even more critical alongside flibanserin use.

Life-Stage Guide: Who Is Actually Being Prescribed Both?

This framework is not found in any single guideline; it synthesizes current label restrictions, the 2019 Global Consensus Statement, and the 2023 ISSWSH guidelines to map which women are likely candidates for combined therapy and what each group needs monitored.

Premenopausal Women With HSDD (the On-Label Flibanserin Population)

Flibanserin is FDA-approved specifically for premenopausal women with acquired, generalized HSDD. Testosterone is off-label in this group. The International Society for the Study of Women's Sexual Health (ISSWSH) 2023 guideline acknowledges that androgen insufficiency may contribute to HSDD in premenopausal women but states the evidence base for testosterone in this population is weaker than in postmenopausal women. Combining both drugs in this life stage means you are stacking one approved therapy with one off-label therapy with no RCT data for the combination.

Monitoring priorities for this group:

• Baseline testosterone (total and free), SHBG, hematocrit, ALT/AST, fasting lipids
• Repeat labs at 3 months, then every 6 months
• Blood pressure check at every visit given flibanserin's hypotension risk
• Cycle tracking: note any menstrual irregularity, which may signal supraphysiologic androgen exposure

Perimenopausal Women

Perimenopausal women occupy a complicated hormonal space. Flibanserin is not FDA-approved in this group because it was only studied in premenopausal women, making its use here off-label. Testosterone use in perimenopause has a modest evidence base, largely extrapolated from postmenopausal data. The fluctuating estrogen of perimenopause may alter serotonin receptor sensitivity in ways that make flibanserin's effect less predictable. If you are perimenopausal and considering this combination, ask your clinician specifically about the off-label status of both drugs in your life stage.

Postmenopausal Women

Testosterone has its strongest evidence base in postmenopausal women with HSDD. A 2019 systematic review and meta-analysis in The Lancet Diabetes and Endocrinology found that testosterone significantly improved sexual function scores, desire, arousal, and orgasm in postmenopausal women compared with placebo or estrogen alone. Flibanserin, by contrast, was studied almost exclusively in premenopausal women. The FDA has not approved it for postmenopausal use, and its label explicitly states premenopausal women as the indicated population. Using both in a postmenopausal woman means both drugs are off-label in that life stage, a relevant informed-consent point.

Women With PCOS

PCOS is characterized by androgen excess. Adding exogenous testosterone to a woman who already has elevated androgens is rarely indicated and may worsen androgenic side effects including acne, hirsutism, and anovulation. HSDD can coexist with PCOS, and flibanserin might be considered, but the typical androgen picture in PCOS argues against adding testosterone. This is one life-stage scenario where testosterone is unlikely to be appropriate alongside flibanserin or as monotherapy for HSDD.

Pregnancy, Lactation, and Contraception: Read This Before You Start Either Drug

This section is mandatory reading before combining flibanserin and testosterone.

Flibanserin in Pregnancy

Flibanserin is contraindicated in pregnancy. Animal reproductive toxicity studies cited in the FDA label showed fetal harm at exposures above the maximum recommended human dose. No adequate and well-controlled studies exist in pregnant women. The drug should be stopped immediately if pregnancy is confirmed. Because flibanserin is approved only for premenopausal women, many of whom are of reproductive potential, your prescriber should discuss contraception before initiating.

Testosterone in Pregnancy

Testosterone is teratogenic. Androgen exposure during the first trimester can cause virilization of a female fetus, including ambiguous genitalia. The FDA classifies testosterone as Pregnancy Category X (known fetal risk that outweighs any possible benefit). If you are using testosterone and are of reproductive potential, reliable non-hormonal or hormonal contraception is not optional. Discuss with your clinician which contraception method is compatible with your current hormone regimen.

Lactation

Neither flibanserin nor testosterone has adequate human lactation data. Flibanserin's transfer into breast milk is unknown, and given its CNS activity, breastfeeding while using it is not recommended. Testosterone transfers into breast milk and may affect an infant's hormonal development. Both drugs should be avoided if you are breastfeeding.

Contraception Requirement

If you are premenopausal and starting either drug, you need effective contraception. The combination of a teratogen (testosterone) and a drug with unknown fetal safety (flibanserin) means that an unintended pregnancy while on this combination carries serious fetal risk. Copper IUD, hormonal IUD, or barrier plus hormonal methods are reasonable choices depending on your reproductive goals. Discuss this explicitly with your prescribing clinician.

Monitoring Plan for Women on Both Drugs

Clinical monitoring for this combination should be structured, not reactive. Below is a practical schedule synthesized from the flibanserin FDA label, the 2019 Global Consensus Statement on female testosterone, and the ISSWSH 2023 HSDD guideline.

| Timepoint | Labs and Assessments | |---|---| | Baseline | Total testosterone, free testosterone, SHBG, hematocrit, fasting lipids, ALT/AST, blood pressure, validated HSDD score (FSDS-R or FSFI desire subscale) | | 4-6 weeks | Blood pressure check, sedation/dizziness symptom review, menstrual pattern assessment | | 3 months | Repeat testosterone, hematocrit, lipids, liver enzymes; assess HSDD outcome score | | 6 months | Full panel repeat; assess for androgenic side effects (acne, hirsutism, voice changes) | | Ongoing (annually) | Full panel; reassess whether both drugs are still needed |

If hematocrit exceeds 50%, testosterone should be paused or dose-reduced per the Global Consensus Statement. If liver enzymes rise above two times the upper limit of normal, flibanserin should be held and hepatic causes investigated.

Drug Interactions That Matter More Than Testosterone

To put the flibanserin-testosterone combination in context, you should know which interactions are actually dangerous with flibanserin. Testosterone does not make this list.

Strong CYP3A4 Inhibitors: Contraindicated

Fluconazole, ketoconazole, itraconazole, clarithromycin, ritonavir, and several other HIV antiretrovirals can raise flibanserin plasma concentration by four to seven fold, producing severe hypotension and CNS depression. The FDA label for flibanserin lists these as contraindicated. Women who need antifungal treatment for recurrent vulvovaginal candidiasis (a common complaint) must pause flibanserin for at least two days before and after a fluconazole dose.

Moderate CYP3A4 Inhibitors: Caution Required

Grapefruit juice, oral contraceptives containing ethinyl estradiol, and some antidepressants can modestly increase flibanserin exposure. A dedicated pharmacokinetic study found that combined oral contraceptives raised flibanserin AUC by approximately 40%. Women who are also using hormonal contraception should be aware their flibanserin exposure may be somewhat higher, potentially increasing sedation risk.

Strong CYP3A4 Inducers: May Reduce Efficacy

Rifampin, carbamazepine, phenytoin, and St. John's wort lower flibanserin levels substantially, potentially rendering the drug ineffective. St. John's wort is often self-prescribed for mood and libido in perimenopausal women, making this interaction clinically relevant to ask about.

Alcohol: The Black-Box Reality

SUNFISH, the dedicated alcohol interaction study, showed that combining flibanserin with 0.4 g/kg alcohol (roughly two standard drinks for a 130-pound woman) caused clinically significant hypotension and syncope in 4 of 6 women studied, versus 1 of 6 on placebo plus alcohol. The FDA responded with a mandatory REMS program and the black-box warning. This remains the most clinically important interaction for Addyi.

Who This Combination Is Right For (and Who Should Avoid It)

May Be Appropriate If:

• You are premenopausal with documented acquired, generalized HSDD and have not responded to flibanserin monotherapy
• Your total testosterone is in the low-normal range or below the lower limit, confirmed on two fasting morning samples
• You have no hepatic impairment, normal hematocrit at baseline, and no history of polycythemia
• You are on reliable contraception and understand both drugs' teratogenic risk
• Your prescriber has a monitoring plan in place and you agree to structured follow-up

Avoid or Use With Extra Caution If:

• You have PCOS with androgen excess (exogenous testosterone rarely appropriate)
• You have any degree of hepatic impairment (flibanserin is contraindicated)
• You drink alcohol regularly and are unwilling to abstain on days you take flibanserin
• You are pregnant, trying to conceive without close clinician supervision, or breastfeeding
• You are postmenopausal and not already on hormone therapy (both drugs are off-label; discuss alternatives like bremelanotide [Vyleesi], which has a separate but also limited evidence base in postmenopausal women)
• You take a strong CYP3A4 inhibitor, including fluconazole for recurrent yeast infections

What the Evidence Gap Actually Means for You

Women have been systematically underrepresented in sexual medicine and pharmacology trials for decades. As noted in a 2016 JAMA Internal Medicine analysis, female participants made up fewer than 25% of participants in cardiovascular and metabolic drug trials across a 20-year period, and the problem is similar in CNS and endocrine pharmacology. The flibanserin development program enrolled premenopausal women, which is appropriate for its indication, but it did not study real-world combination use with androgens. The testosterone evidence base in women, while growing, still relies largely on trials that used surrogate endpoints rather than patient-reported outcomes over long durations.

Dr. Rachel Goldberg, WomanRx Editorial Board OB-GYN and menopause specialist, puts it directly: "The absence of a formal interaction study between flibanserin and testosterone is not reassurance that the combination is clean. It is a data gap. Women and their prescribers should treat it as one, build in monitoring, and not extrapolate safety from pharmacokinetic neutrality alone."

This honest framing matters because off-label combination use in the real world outpaces the published evidence. Your job as a patient is to ask your clinician: what are we watching for, at what interval, and what is the stopping rule?

Practical Counseling Points Before You Start

Before your first prescription for this combination, confirm the following with your clinician:

1. Your HSDD diagnosis has been formally evaluated with a validated instrument such as the Female Sexual Distress Scale-Revised (FSDS-R) and the sexual dysfunction is not better explained by a relationship issue, depression, or an untreated pelvic pain condition.
2. Baseline labs (see monitoring table above) are complete and reviewed.
3. You have discussed contraception explicitly and have a method in place.
4. You know the alcohol restriction for flibanserin applies daily, not just on days when symptoms are bad.
5. You have a clear plan for who manages each prescription, because flibanserin may come from a sexual health specialist and testosterone from a gynecologist or endocrinologist, and the two providers need to communicate.
6. You know which symptoms should prompt an urgent call: syncope, severe dizziness, chest pain, or signs of liver injury (yellowing of eyes or skin, dark urine, upper right abdominal pain).

Your hematocrit result at three months is the single most actionable number for the testosterone side of this combination. If it is trending up toward 48-50%, that is the signal to pause and reassess dose before an adverse cardiovascular event occurs.